Functional and Molecular MRI of the Bone Marrow in Multiple Myeloma

Overview

Journal Br J Radiol

Publisher Oxford University Press

Specialty Radiology

Date 2018 Feb 3

PMID 29393672

Citations 15

Authors

Vassilis Koutoulidis

Nickolas Papanikolaou

Lia A Moulopoulos

Affiliations

Soon will be listed here.

Abstract

MRI plays an important role in the management of patients with plasma cell neoplasms and has been recognized as a biomarker of malignancy in the novel criteria for the diagnosis of multiple myeloma. Functional and molecular MRI techniques such as diffusion-weighted imaging (spinal or whole body), intravoxel incoherent motion, and dynamic contrast enhanced MRI, provide additional information related to tumor cellularity and angiogenesis, which may have prognostic implications for patients with smoldering and symptomatic myeloma. These non-invasive functional techniques are also being evaluated as imaging biomarkers for response assessment in myeloma patients. The purpose of this article is to provide a comprehensive critical review on the current use and potential future applications of these advanced MRI techniques in multiple myeloma. In addition, we will address the technologies involved and describe the qualitative and quantitative characteristics of normal bone marrow with these techniques.

Citing Articles

Recent advances in imaging and artificial intelligence (AI) for quantitative assessment of multiple myeloma.

Liu Y, Huang W, Yang Y, Cai W, Sun Z Am J Nucl Med Mol Imaging. 2024; 14(4):208-229.

PMID: 39309415 PMC: 11411189. DOI: 10.62347/NLLV9295.

Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging.

Den Berghe T, Verberckmoes B, Kint N, Wallaert S, De Vos N, Algoet C Insights Imaging. 2024; 15(1):106.

PMID: 38597979 PMC: 11006637. DOI: 10.1186/s13244-024-01672-1.

How to 19F MRI: applications, technique, and getting started.

Maxouri O, Bodalal Z, Daal M, Rostami S, Rodriguez I, Akkari L BJR Open. 2023; 5(1):20230019.

PMID: 37953866 PMC: 10636348. DOI: 10.1259/bjro.20230019.

Modern imaging techniques for monitoring patients with multiple myeloma.

Pop V, Tomoaia G, Parvu A Med Pharm Rep. 2022; 95(4):377-384.

PMID: 36506611 PMC: 9694753. DOI: 10.15386/mpr-2215.

[Skeletal changes in plasma cell dyscrasias].

Weber T, Mokry T Radiologe. 2021; 61(12):1078-1089.

PMID: 34889973 DOI: 10.1007/s00117-021-00932-1.

References

Griffith J, Yeung D, Antonio G, Lee F, Hong A, Wong S . Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. Radiology. 2005; 236(3):945-51. DOI: 10.1148/radiol.2363041425. View

Zamagni E, Nanni C, Mancuso K, Tacchetti P, Pezzi A, Pantani L . PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. Clin Cancer Res. 2015; 21(19):4384-90. DOI: 10.1158/1078-0432.CCR-15-0396. View

Moulopoulos L, Dimopoulos M, Smith T, Weber D, Delasalle K, Libshitz H . Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 1995; 13(1):251-6. DOI: 10.1200/JCO.1995.13.1.251. View

Dimopoulos M, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies F . Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015; 33(6):657-64. DOI: 10.1200/JCO.2014.57.9961. View

Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F . Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994; 87(3):503-8. DOI: 10.1111/j.1365-2141.1994.tb08304.x. View

Taouli B, Beer A, Chenevert T, Collins D, Lehman C, Matos C . Diffusion-weighted imaging outside the brain: Consensus statement from an ISMRM-sponsored workshop. J Magn Reson Imaging. 2016; 44(3):521-40. PMC: 4983499. DOI: 10.1002/jmri.25196. View

Oh H, Choi J, Park C, Jung C, Lee S, Park Q . Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial. Int J Hematol. 2003; 76(5):465-70. DOI: 10.1007/BF02982813. View

Kricun M . Red-yellow marrow conversion: its effect on the location of some solitary bone lesions. Skeletal Radiol. 1985; 14(1):10-9. DOI: 10.1007/BF00361188. View

Usmani S, Mitchell A, Waheed S, Crowley J, Hoering A, Petty N . Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013; 121(10):1819-23. PMC: 3591801. DOI: 10.1182/blood-2012-08-451690. View

10.

Vande Berg B, Malghem J, Lecouvet F, Maldague B . Magnetic resonance imaging of the normal bone marrow. Skeletal Radiol. 1998; 27(9):471-83. DOI: 10.1007/s002560050423. View

11.

Padhani A, Koh D, Collins D . Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology. 2011; 261(3):700-18. DOI: 10.1148/radiol.11110474. View

12.

Moulopoulos L, Varma D, Dimopoulos M, Leeds N, Kim E, Johnston D . Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology. 1992; 185(3):833-40. DOI: 10.1148/radiology.185.3.1438772. View

13.

Giles S, deSouza N, Collins D, Morgan V, West S, Davies F . Assessing myeloma bone disease with whole-body diffusion-weighted imaging: comparison with x-ray skeletal survey by region and relationship with laboratory estimates of disease burden. Clin Radiol. 2015; 70(6):614-21. PMC: 4443503. DOI: 10.1016/j.crad.2015.02.013. View

14.

Bourillon C, Rahmouni A, Lin C, Belhadj K, Beaussart P, Vignaud A . Intravoxel Incoherent Motion Diffusion-weighted Imaging of Multiple Myeloma Lesions: Correlation with Whole-Body Dynamic Contrast Agent-enhanced MR Imaging. Radiology. 2015; 277(3):773-83. DOI: 10.1148/radiol.2015141728. View

15.

Koh D, Collins D . Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007; 188(6):1622-35. DOI: 10.2214/AJR.06.1403. View

16.

Kastritis E, Moulopoulos L, Terpos E, Koutoulidis V, Dimopoulos M . The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia. 2014; 28(12):2402-3. DOI: 10.1038/leu.2014.230. View

17.

Merz M, Ritsch J, Kunz C, Wagner B, Sauer S, Hose D . Dynamic contrast-enhanced magnetic resonance imaging for assessment of antiangiogenic treatment effects in multiple myeloma. Clin Cancer Res. 2014; 21(1):106-12. DOI: 10.1158/1078-0432.CCR-14-1029. View

18.

Pearce T, Philip S, Brown J, Koh D, Burn P . Bone metastases from prostate, breast and multiple myeloma: differences in lesion conspicuity at short-tau inversion recovery and diffusion-weighted MRI. Br J Radiol. 2012; 85(1016):1102-6. PMC: 3587069. DOI: 10.1259/bjr/30649204. View

19.

Padhani A, Lecouvet F, Tunariu N, Koh D, De Keyzer F, Collins D . METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol. 2016; 71(1):81-92. PMC: 5176005. DOI: 10.1016/j.eururo.2016.05.033. View

20.

Giles S, Messiou C, Collins D, Morgan V, Simpkin C, West S . Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology. 2014; 271(3):785-94. DOI: 10.1148/radiol.13131529. View